These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9596305)

  • 1. Short-term cardiovascular effects of salmeterol.
    Tranfa CM; Pelaia G; Grembiale RD; Naty S; Durante S; Borrello G
    Chest; 1998 May; 113(5):1272-6. PubMed ID: 9596305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
    Rosenthal RR; Busse WW; Kemp JP; Baker JW; Kalberg C; Emmett A; Rickard KA
    Chest; 1999 Sep; 116(3):595-602. PubMed ID: 10492259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia.
    Cazzola M; Imperatore F; Salzillo A; Di Perna F; Calderaro F; Imperatore A; Matera MG
    Chest; 1998 Aug; 114(2):411-5. PubMed ID: 9726723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma.
    Korosec M; Novak RD; Myers E; Skowronski M; McFadden ER
    Am J Med; 1999 Sep; 107(3):209-13. PubMed ID: 10492312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial.
    Chervinsky P; Goldberg P; Galant S; Wang Y; Arledge T; Welch MB; Stahl E
    Chest; 1999 Mar; 115(3):642-8. PubMed ID: 10084469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled beclomethasone dipropionate reverts tolerance to the protective effect of salmeterol on allergen challenge.
    Giannini D; Bacci E; Dente FL; Di Franco A; Vagaggini B; Testi R; Paggiaro P
    Chest; 1999 Mar; 115(3):629-34. PubMed ID: 10084467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?
    Maconochie JG; Minton NA; Chilton JE; Keene ON
    Br J Clin Pharmacol; 1994 Feb; 37(2):199-204. PubMed ID: 7910472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.
    Guhan AR; Cooper S; Oborne J; Lewis S; Bennett J; Tattersfield AE
    Thorax; 2000 Aug; 55(8):650-6. PubMed ID: 10899240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance to the protective effect of salmeterol on allergen challenge can be partially restored by the withdrawal of salmeterol regular treatment.
    Giannini D; Di Franco A; Bacci E; Dente FL; Bartoli ML; Vagaggini B; Paggiaro P
    Chest; 2001 Jun; 119(6):1671-5. PubMed ID: 11399689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 1-week dose-ranging study of inhaled salmeterol in patients with asthma.
    Bronsky EA; Kemp JP; Orgel HA; Bierman CW; Tinkelman DG; van As A; Liddle RF
    Chest; 1994 Apr; 105(4):1032-7. PubMed ID: 7909285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects.
    Bennett JA; Harrison TW; Tattersfield AE
    Eur Respir J; 1999 Feb; 13(2):445-8. PubMed ID: 10065696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.
    Ullman A; Svedmyr N
    Thorax; 1988 Sep; 43(9):674-8. PubMed ID: 2904183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
    Brogden RN; Faulds D
    Allergol Immunopathol (Madr); 1992; 20(2):72-84. PubMed ID: 1359777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of salmeterol.
    Cazzola M; Testi R; Matera MG
    Clin Pharmacokinet; 2002; 41(1):19-30. PubMed ID: 11825095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute cardiovascular effects of salmeterol in subjects with stable bronchial asthma.
    Bagnato GF; Mileto A; Gulli S; Oriti S; Di Cesare E; Cinquegrani M; Bonaiuto M; Saitta A; Purello D'Ambrosio F
    Monaldi Arch Chest Dis; 1996 Aug; 51(4):275-8. PubMed ID: 8909010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac side effects of long-acting beta-2 agonist salmeterol in asthmatic children.
    Tunaoğlu FS; Türktaş I; Olguntürk R; Demirsoy S
    Pediatr Int; 1999 Feb; 41(1):28-31. PubMed ID: 10200132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring.
    Kemp JP; Bierman CW; Cocchetto DM
    Ann Allergy; 1993 Apr; 70(4):316-22. PubMed ID: 8466097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
    Brogden RN; Faulds D
    Drugs; 1991 Nov; 42(5):895-912. PubMed ID: 1723379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of prior treatment with salmeterol and formoterol on airway and systemic beta 2 responses to fenoterol.
    Grove A; Lipworth BJ
    Thorax; 1996 Jun; 51(6):585-9. PubMed ID: 8693438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.